Vaccine Regimens and the Future of Covid-19 Boosters: Heterologous and Homologous Strategies of Vaccination
Keywords:
infection, Covid19, Vaccines, Boosters, mRNAAbstract
The advent of mRNA vaccines against the SARS-CoV-2 virus, which caused the global Covid19 pandemic, has dramatically changed the future of vaccination in the U.S. and abroad. Although existing mRNA vaccines are safe and effective for preventing serious illness from Covid19, much is still unknown about the optimal vaccination strategy. As Covid19, much like influenza, is expected to become endemic in the human population, a yearly vaccine will likely become part of standard health care practices. This review begins with a brief overview of adaptive immunity and explores how different types of vaccines stimulate an immune response. The effectiveness of different vaccination regimens against various diseases and how heterologous vs. homologous vaccination strategies can differentially induce immune response are then discussed. Finally, we conclude by speculating on the future of Covid vaccination and mRNA vaccines in general.
Downloads
References
Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. Chapter 24, The Adaptive Immune System. Available from: https://www.ncbi.nlm.nih.gov/books/NBK21070/
Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. Protein Function. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26911/
Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR el Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, … Beigel JH (2022) Homologous and Heterologous Covid-19 Booster Vaccinations. New England Journal of Medicine, 386(11), 1046–1057. https://doi.org/10.1056/NEJMOA2116414/SUPPL_FILE/NEJMOA2116414_DATA-SHARING.PDF
Au W Y, Cheung P P. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis BMJ 2022; 377 :e069989 doi:10.1136/bmj-2022-069989
Bischoff, WE, Mcnall RJ, Blevins MW, Turner JL, Lopareva E N, Rota PA & Stehle JR (2016) Detection of Measles Virus RNA in Air and Surface Specimens in a Hospital Setting. The Journal of Infectious Diseases, 213(4), 600–603. https://doi.org/10.1093/INFDIS/JIV465
CDC Seasonal Flu Vaccine Effectiveness Studies | CDC. (2019a)(n.d.). Retrieved April 20, 2023, from https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm
Claes, K. J., Geerts, I., Lemahieu, W., Wilmer, A., Kuypers, D. R. J., Koshy, P., & Ombelet, S. (2023). Atypical Hemolytic Uremic Syndrome Occurring After Receipt of mRNA-1273 COVID-19 Vaccine Booster: A Case Report. American Journal of Kidney Diseases, 81(3), 364–367. https://doi.org/10.1053/J.AJKD.2022.07.012
Clinical Guidance for COVID-19 Vaccination | CDC. (2019b)(n.d.). Retrieved April 20, 2023, from https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html
Cohen FS. How Viruses Invade Cells. Biophys J. 2016 Mar 8;110(5):1028-32. doi: 10.1016/j.bpj.2016.02.006. PMID: 26958878; PMCID: PMC4788752.
Comirnaty® (COVID-19 Vaccine, mRNA) | Official Site. (n.d.). Retrieved April 20, 2023, from https://www.covidvaxoption.com/
Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, da Guarda SNF, de Nobrega MM, de Moraes Pinto MI, Gonzalez IGS, Salvador N, Franco MM, de Avila Mendonça RN, Queiroz Oliveira IS, de Freitas Souza BS, Fraga M, Aley P, Bibi S, Cantrell L, Dejnirattisai W, Liu X, Mongkolsapaya J, Supasa P, Screaton GR, Lambe T, Voysey M, Pollard AJ; RHH-001 study team. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022 Feb 5;399(10324):521-529. doi: 10.1016/S0140-6736(22)00094-0. Epub 2022 Jan 21. PMID: 35074136; PMCID: PMC8782575.
Definition of adaptive immunity - NCI Dictionary of Cancer Terms - NCI. (n.d.). Retrieved March 14, 2023, from https://www.cancer.gov/publications/dictionaries/cancer-terms/def/adaptive-immunity
Definition of seropositive - NCI Dictionary of Cancer Terms - NCI. (n.d.). Retrieved May 9, 2023, from https://www.cancer.gov/publications/dictionaries/cancer-terms/def/seropositive
Deng, J.; Ma, Y.; Liu, Q.; Du, M.; Liu, M.; Liu, J. Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health 2022, 19, 10752. https://doi.org/10.3390/ijerph191710752
Ebola virus disease: Vaccines. (n.d.). Retrieved March 14, 2023, from https://www.who.int/news-room/questions-and-answers/item/ebola-vaccines
Falcaro, M., Castañon, A., Ndlela, B., Checchi, M., Soldan, K., Lopez-Bernal, J., Elliss-Brookes, L., & Sasieni, P. (2021). The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. The Lancet, 398(10316), 2084–2092. https://doi.org/10.1016/S0140-6736(21)02178-4
Future COVID-19 booster shots will likely need fresh formulations as new coronavirus variants of concern continue to emerge | Gavi, the Vaccine Alliance. (n.d.). Retrieved April 20, 2023, from https://www.gavi.org/vaccineswork/future-covid-19-booster-shots-will-likely-need-fresh-formulations-new-coronavirus
Grohskopf, L. A., Blanton, L. H., Ferdinands, J. M., Chung, J. R., Broder, K. R., Talbot, H. K., Morgan, R. L., & Fry, A. M. (2022). Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022–23 Influenza Season. MMWR Recommendations and Reports, 71(1). https://doi.org/10.15585/MMWR.RR7101A1
Heidary, M., Kaviar, V. H., Shirani, M., Ghanavati, R., Motahar, M., Sholeh, M., Ghahramanpour, H., & Khoshnood, S. (2022). A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19. Frontiers in Microbiology, 13. https://doi.org/10.3389/FMICB.2022.927306
Hervé, C., Laupèze, B., Del Giudice, G. et al. The how’s and what’s of vaccine reactogenicity. npj Vaccines 4, 39 (2019). https://doi.org/10.1038/s41541-019-0132-6
HPV Vaccine Administration | CDC. (n.d.). Retrieved March 14, 2023, from https://www.cdc.gov/vaccines/vpd/hpv/hcp/administration.html
Jain S, Venkataraman A, Wechsler ME, Peppas NA. Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Adv Drug Deliv Rev. 2021 Oct 9;179:114000. doi: 10.1016/j.addr.2021.114000. Epub ahead of print. PMID: 34637846; PMCID: PMC8502079.
Jain, S., Venkataraman, A., Wechsler, M. E., & Peppas, N. A. (2021). Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Advanced Drug Delivery Reviews, 179, 114000. https://doi.org/10.1016/J.ADDR.2021.114000
Johnson and Johnson vaccine How is it different | VCU Health. (n.d.). Retrieved May 9, 2023, from https://www.vcuhealth.org/news/covid-19/johnson-and-johnson-vaccine-how-is-it-different
Lin, D.-Y., Xu, Y., Gu, Y., Zeng, D., Wheeler, B., Young, H., Sunny, S. K., & Moore, Z. (2023). Effectiveness of Bivalent Boosters against Severe Omicron Infection. New England Journal of Medicine, 388(8), 764–766. https://doi.org/10.1056/NEJMC2215471
Matua GA, Van der Wal DM, Locsin RC. Ebolavirus and Haemorrhagic Syndrome. Sultan Qaboos Univ Med J. 2015 May;15(2):e171-6. Epub 2015 May 28. PMID: 26052448; PMCID: PMC4450778.
Measles, Mumps, and Rubella (MMR) Vaccination | CDC. (n.d.). Retrieved March 14, 2023, from https://www.cdc.gov/vaccines/vpd/mmr/public/index.html
Menni, C., May, A., Polidori, L., Louca, P., Wolf, J., Capdevila, J., Hu, C., Ourselin, S., Steves, C. J., Valdes, A. M., & Spector, T. D. (2022). COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. The Lancet Infectious Diseases, 22(7), 1002–1010. https://doi.org/10.1016/S1473-3099(22)00146-3
Polio Vaccination: What Everyone Should Know | CDC. (n.d.). Retrieved March 14, 2023, from https://www.cdc.gov/vaccines/vpd/polio/public/index.html
Ringe R, Bhattacharya J. Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1). Ther Adv Vaccines. 2013 Jul;1(2):67-80. doi: 10.1177/2051013613494534. PMID: 24757516; PMCID: PMC3967664.
Romero, J. R., & Modlin, J. F. (2015). Poliovirus. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 2, 2073-2079.e2. https://doi.org/10.1016/B978-1-4557-4801-3.00173-9
Thompson, M. G., Pierse, N., Sue Huang, Q., Prasad, N., Duque, J., Claire Newbern, E., Baker, M. G., Turner, N., & McArthur, C. (2018). Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012–2015. Vaccine, 36(39), 5916–5925. https://doi.org/10.1016/J.VACCINE.2018.07.028
Understanding How COVID-19 Vaccines Work | CDC. (n.d.). Retrieved March 14, 2023, from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html
Understanding How COVID-19 Vaccines Work | CDC. (n.d.). Retrieved March 14, 2023, from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html
Vaccine Dosing & Schedule. (n.d.). Retrieved April 20, 2023, from https://www.idsociety.org/covid-19-real-time-learning-network/vaccines/vaccine-dosing--schedule/
Vaccine Types | HHS.gov. (n.d.). Retrieved March 14, 2023, from https://www.hhs.gov/immunization/basics/types/index.html
Vaccine Types | NIH: National Institute of Allergy and Infectious Diseases. (n.d.). Retrieved March 14, 2023, from https://www.niaid.nih.gov/research/vaccine-types
Verbeke, R., Lentacker, I., de Smedt, S. C., & Dewitte, H. (2021). The dawn of mRNA vaccines: The COVID-19 case. Journal of Controlled Release, 333, 511. https://doi.org/10.1016/J.JCONREL.2021.03.043
What are protein subunit vaccines and how could they be used against COVID-19? | Gavi, the Vaccine Alliance. (n.d.). Retrieved March 14, 2023, from https://www.gavi.org/vaccineswork/what-are-protein-subunit-vaccines-and-how-could-they-be-used-against-covid-19
What COVID-19 vaccine side effects do and don’t mean | Nebraska Medicine Omaha, NE. (n.d.). Retrieved April 20, 2023, from https://www.nebraskamed.com/COVID/what-covid-19-vaccine-side-effects-do-and-dont-mean
Wilson, P., Andrews, S. Tools to therapeutically harness the human antibody response. Nat Rev Immunol 12, 709–719 (2012). https://doi.org/10.1038/nri3285
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Diya Sammanna
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license unless indicated otherwise in a credit line to the material. If the material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/
